INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 265 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $711,000 | -6.7% | 12,450 | 0.0% | 0.00% | 0.0% |
Q1 2022 | $762,000 | +16.9% | 12,450 | 0.0% | 0.00% | – |
Q4 2021 | $652,000 | +40.5% | 12,450 | 0.0% | 0.00% | – |
Q3 2021 | $464,000 | -37.7% | 12,450 | -31.8% | 0.00% | -100.0% |
Q2 2021 | $745,000 | -28.9% | 18,250 | -40.9% | 0.00% | 0.0% |
Q1 2021 | $1,048,000 | +6.7% | 30,885 | 0.0% | 0.00% | 0.0% |
Q4 2020 | $982,000 | +23.8% | 30,885 | 0.0% | 0.00% | 0.0% |
Q3 2020 | $793,000 | +74.7% | 30,885 | +74.9% | 0.00% | 0.0% |
Q2 2020 | $454,000 | -17.6% | 17,659 | -50.7% | 0.00% | 0.0% |
Q1 2020 | $551,000 | -43.7% | 35,831 | +25.6% | 0.00% | 0.0% |
Q4 2019 | $979,000 | +248.4% | 28,522 | -24.1% | 0.00% | – |
Q3 2019 | $281,000 | +8.1% | 37,564 | +87.6% | 0.00% | – |
Q2 2019 | $260,000 | -76.3% | 20,020 | -49.3% | 0.00% | -100.0% |
Q1 2016 | $1,097,000 | -87.5% | 39,452 | -75.8% | 0.00% | -90.0% |
Q4 2015 | $8,786,000 | +14.1% | 163,336 | -15.0% | 0.01% | +11.1% |
Q3 2015 | $7,697,000 | – | 192,238 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |